Clinical Pharmacokinetics of Everolimus

Clinical Pharmacokinetics

Volumn 43, Issue 2, 2004, Pages 83-95

  Kirchner, Gabriele I ^a   Meier Wiedenbach, Ivo ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; GELATIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; ITRACONAZOLE; MYCOPHENOLIC ACID; PRAVASTATIN; PREDNISONE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS;

AREA UNDER THE CURVE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DISPERSIBLE TABLET; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HERPES SIMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PANCREAS INSUFFICIENCY; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SINUSITIS; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METABOLIC CLEARANCE RATE; SIROLIMUS; TISSUE DISTRIBUTION;

EID: 1442283866     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443020-00002     Document Type: Review

References (72)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic: I. taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-6
2. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22.98), a new antifugal antibiotic: II. fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727-32
3. Calne RY, Kim S, Saaman A, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; II: 227
4. Boehler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195-7
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42
6. Crowe A, Bruelisauer A, Duerr L, et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999; 27: 627-32
7. Krönke M, Leonard WJ, Depper JM, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A 1984; 81: 5214-8
8. Bierer BE, Holländer G, Frumann D, et al. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes and transplantation biology. Curr Opin Immunol 1993; 5: 763-73
9. Emmel EA, Verweij CL, Durand DB, et al. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989; 246: 1617-20
10. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK506 and rapamycin. J Immunol 1990; 144: 251-8
11. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531-7
12. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660-5
13. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10: 330-6
14. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510
15. Terada N, Lucas JJ, Szepesi A, et al. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun 1992; 186: 1315-21
16. Kuo CJ, Chung J, Fiorentino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358: 70-3
17. Brazelton T, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710-20
18. Dumont FJ. Everolimus Novartis. Curr Opin Investig Drugs 2001; 2: 1220-34
19. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998; 30: 2192-4
20. Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative. Transplantation 1997; 64: 32-5
21. Schuurman H, Ringers J, Schuler W, et al. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737-42
22. Stepkowski SM, Napoli KL, Wang ME, Qu X, et al. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62: 986-94
23. Hausen B, Ikonen T, Briffa N, et al. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: systemic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69: 76-86
24. Hausen B, Boeke K, Berry G, et al. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150-9
25. Kahan BD. The synergistic effects of cyclosporine and sirolimus. Transplantation 1997; 63: 170
26. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 1400-6
27. Schwarz C, Oberbauer R. The future role of target of rapamycin inhibitors in renal transplantation. Curr Opin Urol 2002; 12: 109-13
28. Dumont FJ, Kastner C, Iacovone Jr F, et al. Quantitative and temporal analysis of the cellular interaction of FK506 and rapamycin in T-lymphocytes. J Pharmacol Exp Ther 1994; 268: 32-41
29. Curtis J, Nashan B, Ponticelli C, et al. One year results of a multicenter, open-label trial on safety and efficacy of Certican™ (RAD) used in combination with Simulect, corticosteroids, and full or reduced dose Neoral in renal transplantation [abstract 1335]. Am J Transplant 2001; 1 Suppl.: 474
30. Wilkinson A. Progress in the clinical application of immunosuppressive drugs in renal transplantation. Curr Opin Nephrol Hypertens 2001; 10: 763-70
31. Segarra I, Brazelton TR, Guterman N, et al. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl 1998; 720: 179-87
32. Salm P, Taylor PJ, Lynch SV, et al. Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci J Chromatogr B 2002; 772: 283-90
33. Vidal C, Kirchner GI, Wünsch G, et al. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl)rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection. Clin Chem 1998; 44: 1275-82
34. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporin. Clin Pharmacol Ther 2001; 69: 48-56
35. Kirchner GI, Vidal C, Winkler M, et al. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and ciclosporin including their metabolites in human blood. Ther Drug Monit 1999; 21: 116-22
36. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 2000; 748: 41-53
37. McMahon LM, Luo S, Hayes M, et al. High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system. Rapid Commun Mass Spectrom 2000; 14: 1965-71
38. Brignol N, McMahon LM, Luo S, et al. High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin A (CsA) in whole blood. Rapid Commun Mass Spectrom 2001; 15: 898-907
39. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002; 48: 955-8
40. Deters M, Kirchner G, Resch K, et al. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med 2002; 40: 285-92
41. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002; 36: 981-5
42. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48: 694-703
43. Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ RAD (RAD) in quiescent cyclosporin-prednisone-treated renal transplant recipients. Transplantation 1999; 68: 1100-6
44. Levy GA, Grant D, Paradis K, et al. Pharmacokinetics and tolerability of 40-O-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001; 71: 160-3
45. Doyle RL, Hertz MI, Dunitz JM, et al. RAD in stable lung and heart/lung transplant recipients; safety, tolerability, pharmacokinetics, and impact of cystic fibrosis. J Heart Lung Transplant 2001; 20: 330-9
46. Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996; 43: 449-55
47. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 1998; 15: 1666-72
48. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998; 285: 1104-12
49. Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247-54
50. Tan KKC, Hue KL, Strickland SE, et al. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit 1990; 12: 520-4
51. Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001; 70: 425-30
52. Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323-32
53. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001; 33: 514-5
54. Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care 2001; 7: 242-50
55. Zimmerman J, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405-15
56. Kirchner GI, Winkler M, Mueller L, et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 2000; 50: 449-54
57. Kirchner GI, Mueller L, Winkler M, et al. Long-term pharmacokinetics of the metabolites of everolimus (SDZ RAD) and cyclosporine in renal transplant recipients. Transplant Proc 2002; 34: 2233-4
58. Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42: 95-9
59. Vidal C, Kirchner GI, Sewing KF. Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immuno-suppressant SDZ RAD. J Am Soc Mass Spectrom 1998; 9: 1267-74
60. Hallensleben K, Raida M, Habermehl G. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom 2000; 11: 516-25
61. Lhoest GJ, Gougnard TY, Verbeeck RK, et al. Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide. J Mass Spectrom 2000; 35: 454-60
62. Lhoest G, Hertsens R, Verbeeck RK, et al. In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. J Mass Spectrom 2001; 36: 889-901
63. Van Damme-Lombaerts R, Webb NAY, Hoyer PF, et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 2002; 6: 147-52
64. Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001; 38 (4 Suppl. 2): S22-8
65. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation 2003; 75: 2082-5
66. Kovarik JM, Noe A, Berthier S, et al. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol 2003; 43: 141-7
67. Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002; 42: 222-8
68. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002; 22: 154-9
69. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920-5
70. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 53-8
71. Nashan B. The role of Certican (Everolimus, RAD) in the many pathways of chronic rejection. Transplant Proc 2001; 33: 3215-20
72. Lorber MI, Basadonna GP, Friedman AL, et al. The evolving role of TOR inhibitors for individualizing posttransplant immunosuppression. Transplant Proc 2001; 33: 3075-7